BIOMAT Database Logo BIOMAT Database Logo

[Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis]. 1994

C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Abteilung für Infektionshygiene, Technischen Universität München.

The antimicrobial activity of cefpodoxime (Podomexef, CAS 80210-62-4) against 236 clinical isolates of H. influenzae, Moraxella catarrhalis, Streptococcus pyogenes and Streptococcus pneumoniae was investigated and compared with that of another 8 commonly used oral antibiotics. beta-Lactamase negative, beta-lactamase positive and multiresistant strains of H. influenzae were inhibited by cefpodoxime at a concentration of 0.13 mg/l. 10% of Moraxella catarrhalis isolates were moderately susceptible to cefpodoxime, with minimum inhibitory concentration (MIC) of cefpodoxime ranging between 0.13 and 2.0 mg/l. All isolates of Streptococcus pyogenes and Streptococcus pneumoniae were susceptible to < or = 0.25 mg/l cefpodoxime. Cefpodoxime was clearly more active than the older oral cephalosporins against all species tested. The activity was comparable to that of cefixime against all species except Streptococcus pneumoniae, against which cefpodoxime was more active than cefixime.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D001936 Moraxella catarrhalis Gram-negative aerobic cocci of low virulence that colonize the nasopharynx and occasionally cause MENINGITIS; BACTEREMIA; EMPYEMA; PERICARDITIS; and PNEUMONIA. Branhamella catarrhalis,Mikrokkokus catarrhalis,Moraxella (Branhamella) catarrhalis
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000097623 Cefpodoxime A third-generation cephalosporin antibiotic. Cefpodoxime contains a methoxy group at C-3 of its cephalosporin core. 5-Thia-1-Azabicyclo(4.2.0)oct-2-ene-2-Carboxylic Acid, 7-(((2-Amino-4-Thiazolyl)(Methoxyimino)Acetyl)Amino)-3-(Methoxymethyl)-8-oxo-, Monosodium Salt, (6R-(6alpha,7beta(Z)))-,Cefpodoxime Sodium,Cefpodoxime Sodium Salt,R 3746,R-3746,RU 51746,RU-51746,U 76253A,U-76,253A,3746, R,51746, RU,76253A, U,R3746,RU51746,Salt, Cefpodoxime Sodium,Sodium Salt, Cefpodoxime,Sodium, Cefpodoxime,U 76,253A,U76,253A
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus
D013297 Streptococcus pyogenes A species of gram-positive, coccoid bacteria isolated from skin lesions, blood, inflammatory exudates, and the upper respiratory tract of humans. It is a group A hemolytic Streptococcus that can cause SCARLET FEVER and RHEUMATIC FEVER. Flesh-Eating Bacteria,Streptococcus Group A,Bacteria, Flesh-Eating
D015296 Ceftizoxime A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. Ceftizoxime Sodium,Cefizox,Ceftizoxime Monosodium Salt,FK-749,FK749,FR-13749,SK&F 88373-2,SKF-88373,FK 749,FR 13749,FR13749,Monosodium Salt, Ceftizoxime,SK&F 88373 2,SK&F 883732,SKF 88373,SKF88373,Salt, Ceftizoxime Monosodium,Sodium, Ceftizoxime

Related Publications

C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.
January 1992, Chemotherapy,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
May 2004, The Journal of antimicrobial chemotherapy,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae.
May 2004, BMC infectious diseases,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Antibacterial activity of nine oral antibiotics against Streptococcus pneumoniae, Haemophilus influenzae and Branhamella catarrhalis.
January 1983, Scandinavian journal of infectious diseases. Supplementum,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
October 2016, Antimicrobial agents and chemotherapy,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
September 2004, Journal of the Formosan Medical Association = Taiwan yi zhi,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Nasopharyngeal carriage and antibacterial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Estonian children.
December 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
October 1999, The Journal of antimicrobial chemotherapy,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
[Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
January 2001, Acta medica portuguesa,
C Wallrauch-Schwarz, and D Milatovic, and I Braveny
Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
July 1989, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!